Navigation Links
Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
Date:7/21/2008

ASHBURN, Va., July 21 /PRNewswire/ -- Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.

Dr. Wild is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company. He is a member of the Boards of Directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm. He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation.

Dr. Wild was the Chairman of MedPointe Pharmaceuticals Inc., a privately-held specialty pharmaceutical company based in Somerset (NJ), until its acquisition by Meda AB of Sweden in 2007. He also served as CEO from 2001 until 2006.

Between 1995 and 2000, Dr Wild worked for the Warner-Lambert Company, of Morris Plains (NJ). Starting as President of Warner-Lambert's Parke-Davis (North America) unit, he was promoted to Executive Vice President and President of its global Pharmaceutical Sector in 1996. Before joining Warner-Lambert, Dr. Wild spent 22 years with the Schering-Plough Corporation in various roles culminating as President of its Japanese operations.

Dr. Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).

"We are very fortunate to have Dr. Wild join our board, particularly at this time in Innocoll's aggressive evolution to a world leader in biodegradable surgical products. I have known Tony for a number of years and have found him to be a skillful and successful executive in his prior positions. Innocoll is gaining another professional member to its board to guide the company through this period of ambitious growth," said Rolf Schmidt, Innocoll's Chairman of the board.

"I am excited with the Innocoll products and am impressed with the thorough and well-thought out development plans in place. I look forward to working with the board and management to move the Innocoll portfolio forward to commercialization," said Dr. Wild.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP) and in August 2007 sold its marketing rights, with the exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is currently in phase 3 development in the US for the prevention of surgical site infections. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit http://www.innocollinc.com .


'/>"/>
SOURCE Innocoll Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Innocoll Announces Closing of $30 Million Equity Financing Investment
3. AMT Appoints Director Global Marketing and Sales
4. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
5. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
6. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Transcept Pharmaceuticals Appoints Key Senior Executives
9. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
10. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
11. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):